share_log

Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $12

Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $12

Canaccord Genuity維持對CervoMed的買入評級,將目標價下調至12美元
Benzinga ·  12/12 01:24  · 評級/大行評級

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $65 to $12.

Canaccord Genuity分析師蘇曼特·庫爾卡尼維持CervoMED(納斯達克股票代碼:CRVO)的買入並將目標股價從65美元下調至12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論